Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 63 Receivables Turnover is 2.69 as of Mar. 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 63/100 and a GF Value™ of NT$106.86 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Medeon Biodesign ranks better than 80.91% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medeon Biodesign's Revenue for the
three
months ended in Mar. 2026 was NT$114.3 Mil. Medeon Biodesign's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$42.5 Mil.
Hence, Medeon Biodesign's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.69.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medeon Biodesign Receivables Turnover Related Terms
Medeon Biodesign Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medeon Biodesign (ROCO:6499) has a Receivables Turnover of 2.69 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medeon Biodesign and its competitors. According to the industry distribution chart, Medeon Biodesign ranks #155 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 19.1%.
Is Medeon Biodesign's Receivables Turnover too high?
Medeon Biodesign's current Receivables Turnover is 2.69. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Medeon Biodesign's value of 2.69 is 51.2% below this industry median. Based on the distribution chart, Medeon Biodesign ranks #155 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medeon Biodesign has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #155 out of 812 companies for Receivables Turnover. This places Medeon Biodesign in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Medeon Biodesign's value of 2.69 is 51.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current Receivables Turnover of 2.69 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current Receivables Turnover is 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$106.86, compared to a current price of NT$59.00 — trading 44.8% below its estimated fair value. The current Receivables Turnover is 2.69 and 51.2% below the Medical Devices & Instruments industry median of 5.51. Medeon Biodesign's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Receivables Turnover is 2.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$59.00 is trading 44.8% below its estimated GF Value™ of NT$106.86.
GuruFocus considers Medeon Biodesign to be Possible Value Trap.
Key valuation signals for ROCO:6499:
Receivables Turnover: 2.69
GF Value™: NT$106.86 vs. price of NT$59.00 (44.8% below fair value)
Industry Position: 51.2% below the Medical Devices & Instruments median (#155 of 812)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
63GF Score
Get the complete analysis for ROCO:6499
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
